Replies to post #116463 on Biotech Values

[dav1234]

do you think Gilenya will gain market share at copaxone's expense and potentially lessen mCopax's value to NVS,MNTA?

any conflict of interest in NVS controlling both Gilenya and Sandoz(mCopax)?